表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌治疗方面的研究进展

Clinical developments of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of non-small cell lung cancer

全世界肺癌的发病率不断增加,其中约80%为非小细胞肺癌(non-small cell lung cancer,NSCLC)。多数患者确诊时已失去手术切除机会,针对此类患者的治疗方法匮乏且疗效欠佳。近年来,表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs)为表皮生长因子受体(epidermal growth factor receptor,EGFR)基因敏突变患者带来了巨大的临床获益。随着临床和基础研究的不断深入,EGFR-TKIs越来越受到关注。本文结合相关文献围绕EGFR-TKIs在NSCLC治疗方面的研究进展作一综述。

The incidence of lung cancer around the world is increasing. Of them, about 80% are non-small cell lung cancer（NSCLC）. Most of them are diagnosed at an advanced stage and have lost the chance of surgery, who have quite limited therapeutic strategies, with poor prognosis. Recently, it has been demonstrated that epidermal growth factor receptor tyrosine kinase inhibitors（EGFR-TKIs） are efficacious in patients with epidermal growth factor receptor（EGFR） mutation-positive NSCLC. EGFR-TKIs have currently attracted increasing attention. In this review, we aimed to summarize the latest developments of treatment for NSCLC with EGFR-TKIs.